Bryce Point Capital LLC Invests $445,000 in Keros Therapeutics, Inc. (NASDAQ:KROS)

Bryce Point Capital LLC purchased a new stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 28,127 shares of the company's stock, valued at approximately $445,000. Bryce Point Capital LLC owned 0.07% of Keros Therapeutics at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the company. Geode Capital Management LLC raised its position in shares of Keros Therapeutics by 5.5% in the 4th quarter. Geode Capital Management LLC now owns 765,436 shares of the company's stock valued at $12,120,000 after purchasing an additional 39,815 shares during the last quarter. Clearbridge Investments LLC acquired a new position in Keros Therapeutics during the fourth quarter valued at $3,009,000. Norges Bank purchased a new stake in Keros Therapeutics in the 4th quarter worth approximately $1,027,000. NEOS Investment Management LLC boosted its stake in shares of Keros Therapeutics by 28.4% during the 4th quarter. NEOS Investment Management LLC now owns 35,663 shares of the company's stock worth $565,000 after acquiring an additional 7,885 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in Keros Therapeutics by 585.9% in the 4th quarter. JPMorgan Chase & Co. now owns 213,431 shares of the company's stock worth $3,379,000 after purchasing an additional 182,314 shares during the period. Institutional investors own 71.56% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on KROS. William Blair downgraded Keros Therapeutics from an "outperform" rating to a "market perform" rating in a research report on Thursday, December 12th. BTIG Research downgraded Keros Therapeutics from a "buy" rating to a "neutral" rating in a research note on Thursday, December 12th. Wedbush restated a "neutral" rating and issued a $15.00 price target on shares of Keros Therapeutics in a research note on Tuesday, April 1st. Scotiabank decreased their price objective on Keros Therapeutics from $44.00 to $41.00 and set a "sector outperform" rating on the stock in a research note on Thursday, January 16th. Finally, Truist Financial dropped their target price on shares of Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating for the company in a research report on Wednesday. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $40.33.

Keros Therapeutics Price Performance

Shares of NASDAQ KROS traded up $1.52 during mid-day trading on Thursday, reaching $11.85. 2,560,728 shares of the company traded hands, compared to its average volume of 749,369. The firm has a market cap of $480.46 million, a PE ratio of -2.27 and a beta of 1.39. Keros Therapeutics, Inc. has a fifty-two week low of $9.12 and a fifty-two week high of $72.37. The stock has a fifty day simple moving average of $10.86 and a 200-day simple moving average of $31.41.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share for the quarter, topping analysts' consensus estimates of ($1.36) by $0.22. The company had revenue of $3.04 million during the quarter, compared to the consensus estimate of $37.32 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. As a group, analysts predict that Keros Therapeutics, Inc. will post -4.74 EPS for the current fiscal year.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.